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Abstract
Background: Malignant pleural mesothelioma (MPM) is a difficult-to-treat global disease. Pegylated arginase
(BCT-100) has recently shown anti-tumor effects in hepatocellular carcinoma, acute myeloid leukemia and
melanoma. This study aims to investigate the effects of PEG-BCT-100 in MPM.
Methods: A panel of 5 mesothelioma cell lines (H28, 211H, H226, H2052 and H2452) was used to study the in vitro
effects of BCT-100 by crystal violet staining. The in vivo effects of BCT-100 were studied using 211H and H226 nude
mice xenografts. Protein expression (argininosuccinate synthetase, ornithine transcarbamylase, cleaved PARP,
cleaved caspase 3, cyclins (A2, D3, E1 and H), CDK4 and Ki67) and arginine concentration were evaluated by
Western blot and ELISA respectively. Cellular localization of BCT-100 was detected by immunohistochemistry and
immunoflorescence. TUNEL assay was used to identify cellular apoptotic events.
Results: Argininosuccinate synthetase was expressed in H28, H226, and H2452 cells as well as 211H and H266
xenografts. Ornithine transcarbamylase was undetectable in all cell lines and xenograft models. BCT-100 reduced in
vitro cell viability (IC50 values at 13–24 mU/ml, 72 h) across different cell lines and suppressed tumor growth in
both 211H and H226 xenograft models. BCT-100 (60 mg/kg) significantly suppressed tumor growth (p < 0.01) with
prolonged median survival (p < 0.01) in both xenograft models. Combining BCT-100 with pemetrexed or cisplatin
conferred no additional benefits over single agents. Serum and intratumoral arginine levels were effectively
decreased by BCT-100, associated with cytosolic accumulation of BCT-100 within tumor cells. Apoptosis (PARP
cleavage in 211H xenografts; Bcl-2 downregulation, and cleavage of PARP and caspase 3 in H226 xenografts;
positive TUNEL staining in both) and G1 arrest (downregulation of cyclin A2, D3, E1 and CDK4 in 211H xenografts;
suppression of cyclin A2, E1, H and CDK4 in H226 xenografts) were evident with BCT-100 treatment. Furthermore,
proliferative factor Ki67 was downregulated in BCT-100 treatments arms.
Conclusions: BCT-100 suppressed tumor growth with prolonged median survival partially mediated by intratumoral
arginine depletion resulting in apoptosis and G1 arrest in mesothelioma xenograft models. The findings provide
scientific evidence to support further clinical development of BCT-100 in treatment of MPM.
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Background
Malignant pleural mesothelioma (MPM) arises from ex-
posure to asbestos fibers with a long latency period, which
has been a global health problem for the past few decades.
Its anticipated peak incidence is yet to be reached. Mortal-
ity and morbidity of MPM remain extremely high, as its
treatment is rarely curative. Surgery alone or in combin-
ation with radiotherapy and chemotherapy [1] remains the
standard treatment for early-stage disease. Combination
chemotherapy for advanced disease carries only modest
survival benefit [2]. Proven effective treatment options are
very limited, especially for patients with a poor response
to previous chemotherapy.
Amino acids are essential for different cellular functions
including synthesis of protein and polyamines [3]. Intui-
tively, amino acid depletion may serve as an effective
treatment for those cancers that are highly dependent
on exogenous source of amino acids. Arginine is a
semi-essential amino acid in selected tumors, but can be
replenished intracellularly in normal cells. Therefore
arginine-degrading enzymes (arginase and arginine deimi-
nase (ADI)) have been tested in treating different cancers
that are unable to synthesize arginine [4, 5]. Overexpres-
sion of argininosuccinate synthetase (ASS1) and ornithine
transcarbamylase (OTC) is one of the resistance mecha-
nisms in arginase treatment.
BCT-100 is a pegylated arginase (US FDA IND granted
in March 2012) (Bio-Cancer Treatment International
Limited, Hong Kong), which has been tested in a phase I/
II clinical trial for treatment of hepatocellular carcinoma
(HCC) with encouraging results [6]. In vitro, BCT-100 has
shown anti-tumor effects in HCC [4, 7] and acute myeloid
leukemia (AML) [8] with IC50 values at 100–250 mU/ml
and 100–1250 μU/ml respectively. Arginase exerts anti-
proliferative effects in melanoma [9] and HCC [10] by in-
ducing cell cycle arrest and apoptosis. Interestingly an
early phase clinical trial of arginine depletion with pegy-
lated ADI (ADI-PEG20) in MPM was reported in 2014
[11]. Among those MPM with deficient ASS1 expression
by immunohistochemistry, treatment with ADI-PEG20
achieved good metabolic response with significant im-
provement in progression-free survival (hazard ratio
0.53, 95% CI: 0.31 to 0.90, p = 0.02) compared with
best supportive care alone. However, potentially ser-
ious anaphylactoid reaction to ADI has been reported.
Nonetheless, BCT-100 has been shown in early phase
clinical trials to be very well tolerated without ana-
phylaxis. So far, the effect of BCT-100, with a differ-
ent mechanism of arginine depletion from ADI, has
not been investigated in MPM. We therefore embarked
on this study to evaluate the anti-cancer effects of
BCT-100 in MPM, which could provide a scientific
basis for future clinical development of BCT-100 as a
novel treatment for MPM.
Methods
Cell lines and reagents
A panel of 5 mesothelioma cell lines (NCI-H28 (sarcoma-
toid), MSTO-211H (biphasic), NCI-H226 (epithelioid),
NCI-H2052 (sarcomatoid) and NCI-H2452 (epithelioid))
was purchased and authenticated (American Type Culture
Collection, Manassas, VA, USA). Cells were incubated
in RPMI-1640 medium (Gibco®, Life Technologies,
Carlsbad, California, USA) enriched with 10% fetal bovine
serum (FBS) (Gibco®) in a humidified atmosphere of 5%
CO2 at 37 °C.
Pegylated arginase (BCT-100)
Pegylated arginase (BCT-100, PEG-BCT-100 or rhArg1-
peg5000) was provided by Bio-cancer Treatment Inter-
national Limited.
Cell viability assay
Briefly, cells (5000/well) were incubated with different ac-
tivity units of BCT-100 with/without cisplatin or peme-
trexed. Cells incubated with medium only served as a
negative control. Following incubation for 72 h, cells were
fixed for 10 min with 4% formaldehyde (Sigma-Aldrich,
St. Louis, Missouri, United States) in phosphate-buffered
saline (PBS) and stained for 10 min with 0.05% crystal vio-
let. The plates were washed for 4 times with tap water and
then the cells were lysed with 1% sodium dodecyl sulfate
(SDS) solution (Sigma-Aldrich). Absorbance (595 nm)
was measured using a microplate reader Fluo Star Optima
(Bmg Labtec GmbH, Ortenberg, Germany) [12].
Tumor growth inhibition in vivo
The 211H and H226 xenograft models were created, while
H28, H2052 and H2452 xenografts could not be devel-
oped successfully, by subcutaneous injection of 107 corre-
sponding cells in PBS into the upper back of 18 nude
mice (female, 4–6-week-old, 10–14 g, BALB/cAnN-nu,
Charles River Laboratories, Wilmington, USA). Mice
were randomized into 3 groups after tumor growth
was established. PBS (served as control), BCT-100 (20
and 60 mg/kg twice a week), pemetrexed (Eli Lilly,
Indianapolis, Indiana, USA) (150 mg/kg twice a week)
and/or cisplatin (Cayman, Teaduspargi, Tallinn, Estonia)
(2.5 mg/kg once/week) were administered intraperitone-
ally. Tumor dimension (using standard calipers) and body
weight of mice were measured twice a week and tumor
volume was calculated [volume = length x width x width)/
2] [13]. For humane reasons, mice were sacrificed when
tumor volume reached 600 mm3. Tumor xenografts were
collected. The study protocol was approved by the institu-
tional Animal Ethics Committee (approval reference num-
ber: CULATR 3463-14), and standard humane endpoints
for animal research were applied.
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Study of protein expression with Western blot,
immunohistochemistry and immunofluorescence staining
Western blot was performed as previously described
[12]. Specific primary antibodies [mouse monoclonal
anti-human β-actin (Sigma-Aldrich), anti-ASS1, anti-
OTC, anti-PARP, (Santa Cruz Biotechnology, Inc., Santa
Cruz, California, USA), anti-Bcl-2, anti-cleaved caspase-
3, anti-cyclin A2, D3, E1, H, anti-CDK4 (Cell Signaling
Technology, Danvers, Massachusetts, USA), anti-Ki67
(ImmunoWay Biotechnology Company, Texas, USA),
anti-PEG (RevMAb, San Francisco, USA) antibodies]
and corresponding horseradish peroxidase (HRP)-conju-
gated secondary (Cell Signaling Technology) were pur-
chased. An enhanced chemiluminescence (ECL) kit (GE
Healthcare) was used to detect protein expression. Beta-
actin was selected as reference protein [14].
Immunohistochemistry and immunofluorescence stain-
ing were carried out according to standard protocol. Anti-
cytokeratin 1 (Santa Cruz Biotechnology), anti-PEG and
corresponding Alexa Fluor anti-mouse or anti-rabbit (Life
Technology) antibody were used. The slides were mounted
with Prolong® Gold antifade reagent with 4′,6-diamidino-
2-phenylindole (DAPI, Life Technologies). Photos
were taken with Nikon Ni-U fluorescence microscope
(Nikon, Tokyo, Japan) equipped with camera/detector
Diagnostic Instrument RT3 Slider (Meyer Instruments,
Houston, USA).
Serum arginine concentration detection
L-arginine ELISA kit was purchased from Immundiagnos-
tik (Bensheim, Hessen, Germany). The procedure was car-
ried out according to manufacturer’s protocol. Briefly,
derivatized control, standards and samples were incubated
with L-arginine antibody overnight. Peroxidase conjugate
was added after washing. Stop solution was then added to
cease reaction after incubation with tetramethybenzidine
substrate. Absorbance (450 nm) was measured with a refer-
ence (620 nm) using a microplate reader Fluo Star Optima.
Terminal Deoxynucleotidyl transferase-dUTP Nick End
Labeling (TUNEL) Assay
TUNEL assay was performed according to standard
protocol using Click-iT® Plus TUNEL Assay (Life Tech-
nologies). Formalin-fixed, paraffin embedded tumor
xenograft sections were de-paraffinized, fixed and per-
meablized. Sections were first incubated with terminal
deoxynucleotidyl transferase (TdT) reaction buffer, then
TdT buffer containing EdUTP, TdT and TdT enzyme.
Slides were stained with TUNEL reaction cocktail
(TUNEL reaction buffer, copper protectant, Alexa Fluor®
picoyl azide and TUNEL reaction buffer additive). The
slides were mounted with Prolong® Gold antifade re-
agent with DAPI. Photos were taken with Nikon Ni-U
fluorescence microscope.
Statistical analysis
Experiments were repeated at least 3 times and data
analysed (mean ± standard deviation). The difference
between groups was analysed using Student’s two-tailed
t-test by Prism (GraphPad Software, La Jolla, Southern
California, USA). A p-value < 0.05 defined statistical sig-
nificance (*: p < 0.05, **: p < 0.01, ***: p < 0.001). Survival
time of mice bearing tumor xenografts was defined as
the time lapse between the start of treatment and time
point when humane endpoints were reached. The differ-
ence of median survival between treatment arms was
analysed using log-rank test by Prism.
Results
In vitro activity of BCT-100 in mesothelioma
Treatment with BCT-100 induced a dose-dependent anti-
proliferative effect in all mesothelioma cell lines. The IC50
values in H28, 211H, H226, H2052 and H2452 cells were
14.3 ± 2.0, 13.0 ± 1.8, 22.4 ± 6.0, 20.8 ± 5.6 and 18.6 ±
6.5 mU/ml respectively after 72 h of treatment (Fig. 1a).
Basal in vitro expression of ASS1 and OTC
ASS1 was highly expressed in H28 and H2452 cells,
moderately expressed in H226 cells while not detectable
in 211H and H2052 cells (Fig. 1b). All cell lines were
OTC negative (data not shown). As both ASS1 and OTC
are critical rate-limiting enzymes in the urea cycle re-
sponsible for replenishing intracellular arginine, deple-
tion of either one of them is sufficient for cellular
dependence on exogenous arginine supplementation.
This could possibly explain why BCT-100 was uniformly
effective despite varying ASS1 expression across our
panel of MPM cell lines.
Combination of BCT-100 with cisplatin or pemetrexed
There was no synergism when combining BCT-100 with
cisplatin or pemetrexed in all cell lines (Fig. 1c)
Tumor xenograft growth suppression with BCT-100
After inoculation of 211H or H226 cells for 3 days, obvious
tumors were established. In 211H xenograft, after 20 days
of BCT-100 treatment, the relative tumor volume in the 20
and 60 mg/kg treatment groups were 70.5 and 41.4%
(p < 0.01) that of the control group respectively (Fig. 2a).
In H226 xenograft, after 35 days of BCT-100 treatment,
the relative tumor volume in the 20 and 60 mg/kg treat-
ment groups were 65.5% (p < 0.01) and 44.4% (p < 0.001)
that of the control group respectively (Fig. 2b).
Prolonged median survival with BCT-100 in xenograft
models
The median survival (from start of treatment till reach-
ing humane endpoints) increased from 22 days in con-
trol arm to 38 days in 60 mg/kg BCT-100 treatment arm
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(p < 0.01) in 211H xenograft model (Fig. 2c). Similarly,
the median survival increased from 36.5 days in control
group to 50.5 days in 60 mg/kg BCT-100 treatment arm
(p < 0.01) in H226 xenograft (Fig. 2d).
Combination effects of BCT-100 with pemetrexed or
cisplatin on tumor xenografts
No synergistic effect was observed when combining
BCT-100 with pemetrexed in both xenografts. In 211H
xenograft model, both BCT-100 and pemextrexed exerted
similar tumor suppressive effect (Fig. 3a). In H226 xeno-
graft model, only BCT-100 showed significant tumor sup-
pression but not pemetrexed (Fig. 3b).
In 211H xenograft model, no beneficial effect was
noted when combining BCT-100 with cisplatin (Fig. 3c).
More importantly, liver cirrhosis was observed in all
mice in BCT-100/cisplatin arms. Therefore, such com-
bination was not pursued in H226 xenograft model.
Basal in vivo expression of ASS1 and OTC
ASS1 was highly expressed in H226 xenograft while only
weakly detected in 211H xenograft (Fig. 4a). Both xeno-
grafts were OTC negative (data not shown).
In vivo arginine depletion by BCT-100
The serum arginine concentration in control group was
98 ± 36 μM in both xenograft models. In 211H xenograft,
the serum arginine concentration decreased to 24 ± 5 and
14 ± 5 μM in 20 and 60 mg/kg BCT-100 treatment groups
respectively (p < 0.001), with significant dose-dependent
difference between treatment arms (p < 0.001) (Fig. 4b(i)).
In H226 xenograft, the serum arginine concentration
also reduced to 14 ± 4 and 13 ± 4 μM in 20 and 60 mg/
kg BCT-100 treatment groups respectively (p < 0.001)
(Fig. 4b(ii)), though there was no significant between-
group difference.
In 211H xenograft, intratumoral arginine content de-
creased from 9.7 ± 2.3 nmole/mg protein in the control
(See figure on previous page.)
Fig. 1 Relative cell viability upon BCT-treatment, basal expression of ASS1 and combination effect of BCT-100 with cisplatin or pemetrexed in a panel
of mesothelioma cell lines. a BCT-100 reduced cell viability in a dose-dependent fashion. b ASS1 was found in H28, H226 and 2452 cells but not in
211H and H2052 cells. c No synergistic effect in combination of BCT-100 with cisplatin or pemetrexed in different mesothelioma cell lines
Fig. 2 BCT-100 suppressed tumor growth and increased median survival in MPM xenograft models. BCT-100 inhibited tumor growth in a dose-dependent
manner in (a) 211H and (b) H226 xenografts. BCT-100 (60 mg/kg) increased median survival in (c) 211H and (d) H226 xenograft models
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arm to 5.3 ± 1.1 nmole/mg protein (20 mg/kg BCT-100
arm, p < 0.001) and 3.4 ± 0.7 nmole/mg protein (60 mg/
kg BCT-100 arm, p < 0.001). There was significant dose-
dependent intratumoral arginine depletion among BCT-
100 treatment groups (p < 0.001) (Fig. 4b(iii)). In H226
xenograft, intratumoral arginine content declined from
Fig. 3 Combination effects of BCT-100 and pemetrexed or cisplatin in MPM xenograft models. No synergistic or additive effect was observed
when combining BCT-100 with pemetrexed in (a) 211H and (b) H226 xenograft models. The tumor suppressive effect of BCT-100 was comparable
to pemetrexed in 211H xenograft model. Pemetrexed exerted no tumor suppression in H266 xenografts. c There was no beneficial effect when
combining BCT-100 with cisplatin in 211H xenograft model
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9.1 ± 2.5 nmole/mg protein in the control group to
6.2 ± 1.8 nmole/mg protein (20 mg/kg BCT-100 arm,
p < 0.001) and 4.3 ± 1.3 nmole/mg protein (60 mg/kg
BCT-100 arm, p < 0.001). There was also significant dose-
dependent intratumoral arginine depletion between 20
and 60 mg/kg BCT-100 groups (p < 0.01) (Fig. 4b(iv)).
Penetration of BCT-100 into tumor xenografts
Since BCT-100 was linked to polyethylene glycol (PEG),
anti-PEG antibody was used to identify the location of
BCT-100. Intratumoral BCT-100 was found in BCT-100
treatment arms in 211H (Fig. 4c(i)) and H226 (Fig. 4c(ii))
xenograft models in a dose-dependent manner. BCT-100
was found mostly in the central part of tumor xenografts as
shown by immunohistochemistry (IHC) in 211H (Fig. 4d(i))
and H226 (Fig. 4d(ii)) xenograft models.
The compartmentalization of BCT-100 was deter-
mined using immunofluorescence staining. DAPI (blue
color) and cytokeratin 1 (red color) were used to identify
the location of nucleus and cytoplasm respectively. PEG
staining (green color) was shown to overlap mainly with
cytokeratin 1 staining in both 211H (Fig. 4e(i)) and
H226 (Fig. 4e(ii)) xenograft models.
Apoptosis induced by BCT-100 in xenograft models
PARP cleavage was observed in 60 mg/kg BCT-100
treatment arm in 211H xenograft (Fig. 5a). Downregula-
tion of Bcl-2 as well as upregulation of cleaved caspase 3
(CC3) and cleaved PARP (cPARP) were also noted in
60 mg/kg BCT-100 treatment group in H226 xenograft
(Fig. 5b). CC3 was mainly located in the central part of
tumor xenograft as shown by IHC staining in H226
xenograft (Fig. 5c).
In TUNEL assay, TUNEL-positive DNA strand breaks
were noted in BCT treatment arms in 211H (Fig. 5d(i))
and H226 (Fig. 5d(ii)) xenografts.
G1 arrest induced by BCT-100 in vivo
G1 arrest was indirect evidenced by alteration of related
protein expression in cell cycle. Cyclin A2, D3, E1 and
CDK4 were downregulated by BCT-100 in 211H xeno-
graft (Fig. 5e(i)) while cyclin A2, E1, H and CDK4 were
suppressed by BCT-100 in H226 xenograft (Fig. 5e(ii)).
Expression of Ki67 was suppressed by BCT-100 in both
211H (Fig. 5f(i)) and H226 (Fig. 5f(ii)) xenograft models.
Discussion
BCT-100 showed antiproliferative effects in MPM as
demonstrated by crystal violet cell viability assay in our
cell line model. In 211H and H226 xenograft models,
BCT-100 (60 mg/kg) suppressed tumor growth accom-
panied by prolonged median survival. Serum arginine
concentration and intratumoral arginine content de-
creased significantly in BCT-100 treatment groups, asso-
ciated with apoptosis and G1 arrest.
Amino acid depletion is a novel approach for cancer
treatment. Asparagine and arginine are both essential
amino acids in cancer cells, but not in normal human cells.
ADI and BCT-100 were pre-clinically and clinically proven
to inhibit arginine auxotrophic tumors with ADI targeting
ASS1 deficient cancers and BCT-100 targeting ASS1 and/
or OTC negative cancers. Furthermore, ADI-PEG20 has
been shown to have interesting anti-cancer effect on ASS-
deficient cancers including lymphoma, head and neck can-
cer, small cell lung cancer, pancreatic cancer and breast
cancer through apoptosis and cell cycle arrest [15].
Arginine depletion carries a systemic effect that may
involve the tumor microenvironment. Therefore, we be-
lieve that the effect of BCT-100 would be better studied
using xenograft models rather cell line models. Since the
in vivo tumor suppressive effect of BCT-100 alone has
been observed in our study, the combination of BCT-
100 and current active chemotherapeutic agents (peme-
trexed or cisplatin) in MPM was further investigated. In
211H xenograft model, the effect of BCT-100 was simi-
lar to pemetrexed or cisplatin. More importantly, BCT-
100 showed a superior effect than pemetrexed in H226
xenograft. It has been shown that thymidylate synthase
was highly expressed in H226 xenograft [14] which can
explain the relative pemetrexed resistance in H226 xeno-
graft. Nonetheless, the combination of BCT-100 and
pemetrexed did not reveal any additional benefit com-
pared with single agents. As serious side effect (liver cir-
rhosis) was found with BCT-100/cisplatin combination
in 211H xenograft model, this combination was not pur-
sued further in our study.
The common side effects of cisplatin and pemetrexed
combination chemotherapy include severe nausea and
vomiting [16], myelosuppression and neutropenia [17].
With good tolerability of BCT-100 shown in early clin-
ical trials [6], BCT-100 may potentially serve as an alter-
native therapeutic agent, though not in combination
(See figure on previous page.)
Fig. 4 Basal expression of ASS1, BCT-100-induced arginine depletion and localization of BCT-100 in xenograft models. a ASS1 was highly
expressed in H226 xenograft but relatively low in 211H xenograft. BCT-100 decreased serum arginine concentration in (b)(i) 211H and (b)(ii) H226
xenograft models. BCT-100 reduced intratumoral arginine level in a dose-dependent fashion in (b)(iii) 211H and (b)(iv) H226 xenografts. Intratumoral
level of PEG-BCT-100 was increased in BCT-100 treatment arms with a dose-dependent manner in (c)(i) 211H and (c)(ii) H226 xenografts. BCT-100 was
mostly located in the central part of tumor in (d)(i) 211H and (d)(ii) H226 xenografts, with cytosolic compartmentalization ((e)(i), (e)(ii)) as shown by
immunoflorescence staining (pictures taken with 400X magnification)
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with existing chemotherapy, in the clinical management
of MPM. This is particularly true among patients with
MPM that overexpress thymidylate synthase resulting in
pemetrexed resistance.
MPM can be sub-divided into epithelioid, sarcomatoid
and biphasic histological sub-types, with poorer survival
among patients with sarcomatoid and biphasic meso-
thelioma [18]. BCT-100 showed tumor suppressive effect
in biphasic 211H and epithelioid H226 MPM xenograft
models. However, no sarcomatoid mesothelioma xeno-
graft model could be developed in this study for assess-
ment of the efficacy of BCT-100.
BCT-100 effectively decreased serum arginine concen-
tration to 24 and 14% that of control mice in both xeno-
graft models even with low-dose (20 mg/kg) BCT-100
treatment, which could not completely explain the dose-
dependent tumor suppression. On the other hand, the
dose-dependent arginine depletion was better demon-
strated within the intratumoral compartment, which
should be more relevant to the activity of BCT-100 on
the tumor xenografts. This is in line with the finding of
increased intratumoral BCT-100 level with higher dose of
BCT-100 treatment, suggesting intratumoral on top of
systemic arginine depletion. The intratumoral localization
of BCT-100 in MPM xenografts was mainly cytosolic,
which is similar to previous finding [19].
Apoptotic cells were increased after incubating melan-
oma A375 cells with BCT-100 using annexin-V binding
assay [9]. Caspase-dependent cellular apoptosis was acti-
vated by BCT-100 in human hepatoma HepG2 and
PLC/PRF/5 cells [4]. Nonetheless, the in vivo evidence
of apoptosis has not yet been shown previously. In our
study, apoptosis was induced by BCT-100 in mesotheli-
oma xenograft models as evidenced by alteration of key
apoptosis-related factors and TUNEL positive-staining
in BCT-100 treatment arms in both xenografts.
It has been shown that BCT-100 could induce G2/M
arrest in HCC Hep3B cells, S arrest in HCC HepG2 and
PLC/PRF/5 cells [10], and G2/M arrest in melanoma
A375 cells [9]. On the other hand, G0/G1 arrest was ob-
served with BCT-100 treatment in acute myeloid
leukemia cells [19]. BCT-100-induced G1 arrest was
evidenced by altered expression of relevant cell cycle
regulators in our in vivo mesothelioma study, suggesting
that the exact point of cell cycle arrest could be cell line-
or tumor-specific. Ki67 is a functional antigen found in
the nucleus that serves as a proliferative marker control-
ling all phases of the cell cycle [20]. Downregulation of
Ki67 by BCT-100 in both MPM xenografts is consistent
with suppression of G1 arrest-related factors.
BCT-100 reduced relative cell viability in Hep3B
(hepatoma), A375 (melanoma), 211H (mesothelioma)
and H226 (mesothelioma) cells with IC50 values of 100,
86, 13 and 20 mU/ml respectively [4, 9]. The effective
dose of BCT-100 used was about 27000 U/kg/week in
both melanoma and HCC xenograft models [4, 9] while
only about 3000 U/kg/week was administered in MPM
xenograft models in our study. The correlation between
in vitro and in vivo efficacy of BCT-100 seems to be
quite consistent among different tumor types. Further-
more, the dosage of BCT-100 given in a clinical trial for
treatment of advanced HCC was 1600 U/kg/week [6],
which was equivalent to about 20000 U/kg/week in mice
models [21]. The effective dose of BCT-100 used in this
study was only 3000 U/kg/week which was much lower
than that the equivalent dose used in the clinical trial.
The dose of BCT-100 used was likely cancer-specific
which was possibly due to different types of cancer cells
having different arginine and metabolic requirements
[6]. Our finding of the relatively greater sensitivity of
MPM than HCC or melanoma to BCT-100 holds prom-
ise for future clinical development of BCT-100 in the
treatment of MPM. Ideally, the efficacy of BCT-100 in
MPM can be better evaluated in primary cultures that
provide closer mimicry of tumor microenvironment.
However, MPM is a rare disease in Hong Kong with only
about 20 new cases per year, which precludes any feasi-
bility of experiments using primary cultures derived
from patients’ tumor samples.
Recently, an early-phase clinical trial was conducted
using pegylated arginase (BCT-100) at 1600 U/kg/week
in the treatment of advanced HCC [6]. A significantly
improved progression-free survival was observed in pa-
tients with adequate arginine depletion (ADD) (<8 μM
serum arginine concentration) for more than 2 months
compared with those with ADD for less than 2 months
(6.4 vs 1.7 months, 95% CI: 1.67–1.73, p = 0.01). Overall
survival was also improved with BCT-100 treatment
compared with untreated HCC patients (6.4 vs <2–3
months [22]). Adverse events were mostly mild (pain,
(See figure on previous page.)
Fig. 5 BCT-100 induced apoptosis and G1 arrest in MPM xenografts. Upon BCT-100 (60 mg/kg) treatment, (a) cleaved PARP (cPARP) was upregulated
in 211H xenograft, (b) downregulation of Bcl-2 as well as cleavage of caspase 3 (CC3) and PARP (cPARP) in H226 xenograft and (c) CC3 was mainly
found in the core part of tumor in H226 xenograft. (d) Nuclei were stained by DAPI (blue signal). There was no green TUNEL signal in control groups
in both xenografts. The TUNEL signal was noted in both treatment arms in (d)(i) 211H and (d)(ii) H226 xenografts. Overlay of TUNEL and DAPI
indicated DNA breaks were mainly located in nuclei. e(i) BCT-100 reduced the expression of cyclin A2, D3, E1 and CDK4 in 211H xenograft. e(ii)
Downregulation of cyclin A2, E1, H and CDK4 by BCT-100 was observed in H226 xenograft. BCT-100 induced downregulation of proliferation factor
Ki67 in (f)(i) 211H and (f)(ii) H226 xenografts
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insomnia, loss of appetite, constipation, fatigue, vomiting
and nausea) with BCT-100 treatment [6]. Further clinical
development of BCT-100 in treatment of unresectable
HCC is currently underway.
Conclusion
BCT-100 as a single agent has demonstrated significant in
vitro and in vivo anti-tumor effects in MPM, which are
mediated by intratumoral arginine depletion resulting in
apoptosis and cell cycle arrest.
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